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Abstract
Introduction: Like many countries in sub-Saharan Africa, Kenya is experiencing a rapid rise in the burden of non-communica-
ble diseases (NCDs): NCDs now contribute to over 50% of inpatient admissions and 40% of hospital deaths in the country.
The Academic Model Providing Access to Healthcare (AMPATH) Chronic Disease Management (CDM) programme builds on
lessons and capacity of HIV care to deliver chronic NCD care layered into both HIV and primary care platforms to over
24,000 patients across 69 health facilities in western Kenya. We conducted a cost and budget impact analysis of scaling up
the AMPATH CDM programme in western Kenya using the International Society for Pharmacoeconomics and Outcomes
Research guidelines.
Methods: Costs of the CDM programme for the health system were measured retrospectively for 69 AMPATH clinics from
2014 to 2018 using programmatic records and clinic schedules to assign per clinic monthly costs. We quantified the additional
costs to provide NCD care above those associated with existing HIV or acute care services, including clinician, staff, training,
travel and equipment costs, but do not include drugs or consumables as they would be paid by the patient. We projected the
budget impact of increasing CDM coverage to 50% of the eligible population from 2021 to 2025, and compared it with the
county budgets from 2019.
Results: The per visit cost of providing CDM care was $10.42 (SD $2.26), with costs at facilities added to HIV clinics $1.00
(95% CI: $2:11 to $0.11) lower than at primary care facilities. The budget impact of adding 26,765 patients from 2021 to
2025 to the CDM programme was 3,088,928 under constant percent growth, and 3,451,732 under steady-state enrolment.
Scaling up under the constant percent growth scenario resulted in 12% cost savings in the budget impact. The county pro-
grammatic CDM cost in 2025 was <1% of the county healthcare budgets from 2019.
Conclusions: The budget impact of scaling up AMPATH’s CDM programme will be driven by annual growth scenarios, and
facility/provider mix. By leveraging task shifting, referral systems and partnering with public and non-profit clinics without
NCD services, AMPATH’s CDM programme can provide critical NCD care to new, rural populations with minimal financial
impact.
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1 | INTRODUCTION
In low- and middle-income countries (LMICs), the burden of
non-communicable diseases (NCD) is rapidly increasing due to
ageing populations, lifestyle and dietary changes, rapid urban-
ization, and improved control of communicable diseases [1].
Of the 14 million annual premature deaths attributable to
NCDs, 90% occur in LMICs where availability and use of
appropriate NCD services is insufficient, especially in poorer
and rural areas [2,3]. In Kenya 14% of adults have three or
more risk factors for cardiovascular disease (CVD) and 25%
have hypertension or diabetes as of 2015, with models pre-
dicting increasing growth [4,5]. The prevalence of NCDs is
also rising among the HIV infected population, increasing mor-
tality and further complicating chronic disease treatment
including adherence to antiretroviral (ART) medications [6,7].
To address this emerging epidemic, the Kenyan Ministry of
Health (MOH) developed the National Strategy for the
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Prevention and Control of Non-Communicable Diseases to
implement efficient mobilization and utilization of resources
[8]. One of the guiding principles of this strategy is integration
of non-communicable disease control into existing primary
care and HIV treatment platforms, as NCD care had histori-
cally only been available in hospitals. In addition to better
coordinating treatment for NCD/HIV comorbidities associated
with ageing, this strategy leverages the advancements in
health systems infrastructure, training, and workforce task-
shifting developed for HIV care platforms to address the sys-
temic deficits in chronic disease care [9].
An HIV/NCD modelling study in Kenya estimated that inte-
grated HIV and NCDs could avert more than 43,000 CVD-
related deaths over 15 years but that the cost required to
fully scale-up the intervention would require a 12% increase
in Kenya’s total health budget [10]. Another study in Uganda
also demonstrated cost-effectiveness of integrated HIV/NCD
care but noted that adding this integration would account for
4% of the national HIV budget [11].
Layering chronic disease care into existing HIV programmes,
and further expanding that integration within effective primary
care platforms, strengthens the capacity of the public-sector
healthcare system to treat NCDs under resource constraints
[12]. In western Kenya, the Academic Model Providing Access
to Healthcare (AMPATH) chronic NCD care programme has
been integrated with existing HIV and primary care pro-
grammes and shown to be effective for improving retention in
care and hypertension control among HIV positive patients,
which addresses an important gap in NCD care delivery for
this population [13-16]. The flexibility of this integrated model
allows for programme expansion based on local needs and
existing health system capacity. Policy changes that aim to
finance public programmes and increase enrolment in and
reimbursements for the National Health Insurance Fund
(NHIF) require a clear understanding of the affordability of
NCD treatment programmes. To inform the affordability of
scaling up chronic NCD care within AMPATH’s existing HIV
and primary care programme in western Kenya, we measured
the cost of the programme from a health system perspective
from 2014 to 2018 and modelled the budget impact of
increasing programme coverage from 2021 to 2025 (see
Research Agenda).
2 | METHODS
2.1 | Study design
We conducted a retrospective costing and applied the Inter-
national Society for Pharmacoeconomics and Outcomes
Research (ISPOR) framework to perform the Budget Impact
Analysis (BIA [17]. We measured the incremental costs to the
health system of layering the CDM programme into existing
outpatient public and non-profit primary care and HIV care
platforms in western Kenya. We constructed a static deter-
ministic model to quantify the budget impact of increasing the
CDM programme to achieve the health systems NCD treat-
ment target of drug therapy and counselling coverage of 50%
of the eligible population [18], which is one of nine voluntary
global targets set by the WHO’s Global Monitoring Frame-
work for NCDs and adapted for the Kenyan National Strategy
for The Prevention And Control of NCDs.
2.2 | Study setting
In western Kenya, the AMPATH provides comprehensive HIV
care for more than 140,000 HIV-infected patients through-
out a catchment area of over 3.5 million people. In collabora-
tion with the MOH, AMPATH formed its Chronic Disease
Management (CDM) programme with the goal of leveraging
existing health delivery platforms to expand treatment
capacity.
Costing was conducted for all 69 AMPATH-affiliated health
facilities providing chronic NCD care, including 23 HIV care
facilities. CDM care is delivered in 37 dispensaries, 16 health
centres, 15 primary hospitals, and the Moi Teaching and
Referral Hospital (MTRH) (Tables S1 and S2).
The CDM programme draws from the model of task-shift-
ing and community partnerships build upon the capacity and
willingness of established healthcare delivery systems [19]. In
addition to training nurses who are located at the CDM clin-
ics, clinical officers, pharmacists and physicians are based out
of regional hospitals, and travel throughout the county to
dispensaries, health centres and primary care hospitals for
regular NCD visit days, with frequency driven by patient
demand and clinician workloads [20-23]. More complex
patients are referred to higher levels of care as needed, and
the programmatic staff and AMPATH Medical Records Sys-
tem (AMRS) provides consistent chronic disease tracking.
The CDM programme was initially delivered on top of
AMPATH’s HIV care but has since expanded across other
existing MOH or not-for-profit facilities, and now accepts
NCD patients regardless of HIV status [9]. Partnering with
established health facilities enables the CDM programme to
provide comprehensive care without having to create new
facilities. This study was conducted in the counties of Bun-
goma, Busia, Kisumu, Nandi, Trans Nzoia and Uasin Gishu,
where AMPATH has established local partnerships and vari-
able CDM program penetration.
2.3 | Ethics approval
This retrospective costing and modelling study used de-
identified data from the AMRS, which does not require indi-
vidual informed consent. The Institutional Research and Ethics
Committee at the Moi University School of Medicine and the
Institutional Review Board at Brown University approved use
of these de-identified data and waived informed consent
requirements.
2.4 | Input data and sources
We quantified the additional costs of the CDM programme
outside of those incurred by the existing primary and HIV
care programmes, including training, clinicians, programme and
data management staff, medical records though the AMRS
and testing/monitoring equipment. Consumables and medica-
tions are paid for by patients and were not included in this
analysis.
Monthly programme costs from 2014 to 2018 were col-
lected via key informant interviews with programme officers
and clinicians, CDM programme records, and AMPATH
employee salary scales and standard operating procedures.
Facility costs were assigned using monthly patient visits and
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the CDM programme’s monthly schedule, which captured vari-
ation in visit frequency and clinical staff over time (full cost
categorizations and facility attributes are provide in Tables S5,
S6,S7,S8,S9,S10). Personnel costs included clinician salary,
training costs, and programmatic staff salary. Travel costs are
incurred when clinical staff travel to facilities from the referral
hospitals in each county or MTRH. They are calculated using
round trip distance to the geocoded facility location multiplied
by the cost per kilometre provided by the AMPATH Care
Standard Operating Procedures for Clinical Travel. Costs of
equipment used for diagnosis and monitoring were based on
market prices and annualized using key informant reports of
equipment lifetime under standard use in the programme [24].
All facilities used electronic blood pressure cuffs to assess
blood pressure, and glucometer for blood glucose, and either
handheld or bench-top laboratory instruments for A1C mea-
surement. Monthly patient visits by clinic were derived from
the AMRS reports.
2.4.1 | Cost analysis
All costs were standardized to AMPATH’s 2018 payment
schedules and standard operating procedures, and all calcula-
tions used the average 2018 exchange rate of 101.35 Kenya
shillings to one United States dollar [25]. Costs analyses
include a description of monthly costs per facility and annual
mean cost of facilities and patient visits. We assessed the dif-
ferences in costs between the CDM facilities added to the
HIV platform compared to CDM facilities added to a primary
care platform controlling for differences in facility levels,
transport costs, and time trends, and a non-linear transforma-
tion of number of facility visits to account for economies of
scale using the following formula:
Cost ¼b0 þ b1HIVClinicþ b2Facility Patient Visits
þ b3 log Facility Patient Visitsþ b4 Facility Level
þ b5 Trasportþ b6 TimeTrend
2.5 | Budget impact model
In the model we included the following incremental costs:
clinic visits, clinical staff salary, programmatic staff salary,
training, and travel, as well as incremental equipment costs
by clinic. We used normative CDM treatment guidelines to
transform the incremental patient visit costs to the annual
total patient costs based on management plans reflecting
the treatment complexity and attrition among the CDM
population (see Tables S5,S6,S7,S8,S9,S10 for more detail)
[26].
2.5.1 | Target population
The BIA estimates the cost of scaling up CVD care including
hypertension and diabetes treatment to reach 50% of the eli-
gible population by 2025 for the six counties where AMPATH
is partnered with the public health system (Figure 1). The eli-
gible population for the CVD care target are people over 40
with a 10-year CVD risk profile ≥30% or CVD, which is 7.5%
of the population ≥40 [5]. Of the six counties, two had
achieved the target, and CDM did not need to be further
scaled in those counties. The BIA assumptions are provided in
Appendix Table S11.
2.5.2 | Time horizon
We modelled growth over a five-year time horizon from 2021
to 2025 to align with the 2025 target achievement date of
the WHO’s Global Monitoring Framework for NCDs and
Kenya’s National NCD Strategy.
2.5.3 | Scenario analysis
We modelled the scale-up needed to achieve these the tar-
geted number of patients within five years per country in two
ways: steady-state enrolment where the same number of
patients are added annually, and a constant growth percent-
age where the number of new patients is derived as a percent
of the prior year’s total patients.
2.5.4 | Budget holder
The budget holder is the county government that allocates
health funding and care delivery. However, since most health
policy and financing is at the national level we also present
results for the total programme. As availability of NCD care is
very low for this patient population outside of the CDM pro-
gramme, we did not include a replacement scenario where
patients can receive NCD care elsewhere. Due to the short
time frame used in the BIA and the need to budget spending
in each year, we do not include discounting.
2.5.5 | Cost inputs
The cost is quantified separately for each facility level as the
largest per patient cost variation was across facility levels. To
account for patient-volume economies of scale and limits of
individual clinics, the median monthly patient visits for each
facility level was used for the incremental cost-per-patient,
and to quantify the number of facilities and therefore the
amount of addition equipment needed. Equipment costs are
included in the year they would be purchased. The proportion
of the total additional patients allocated to each facility level
is based on historical trends in proportion of patients in each
level. The BIA is reported separately for each county and for
the whole programme.
2.6 | Sensitivity analyses
We conducted multivariate and univariate deterministic sensi-
tivity analysis of the costs inputs, median patients per facility,
and two alternative distributions of new patients across the
facility levels, one prioritizing growth in primary care facilities,
and another demonstrating equal growth by facility type. We
conducted sensitivity analysis on the travel cost using the
interquartile range of the whole programme because counties
with fewer programmes may be more closely grouped
together and would not accurately reflect programme expan-
sion throughout the entire county.
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3 | RESULTS
Figure 2 provides the monthly costs among active facilities
from 2014 to 2018. While the average costs are stable over
time, the variation reflects differences in provider visits and
monthly patient visits. MTRH is a clear outlier with monthly
costs>$3,500 across the study period. There are also distinct
distributions in costs by facility type, despite more overlap
across the levels of the health system. Because the costing is
reflective of a dynamic treatment program that is adaptive to
patient demand and programme capacity, the number of facili-
ties and cost of each varies throughout the period of study.
Due to this variation, we separate the levels of care and
present the mean and standard deviation (SD) of annual and
monthly costs by facility and patient visits in Table 1. The
average annual facility cost of CDM varied across the four
levels from $3,862 (SD: 373) per dispensary to $72,671 (SD:
10,404) at MTRH. For each level of care, the cost of clinicians
and administrative costs made up the largest proportion of
total costs. The average total cost per patient-visit ranged
from $8.21 (SD: $2.21) at primary hospitals to $18.42 (SD:
$3.61) at MTRH. Per facility annualized equipment costs var-
ied by level from $167 (SD 35) to $283 (SD: $39). MTRH
had a considerably higher average clinician cost at $64,073
Figure 1. Budget impact schematic. This analysis models the change in total target population, increasing the number of CDM facilities, and
predicted increase in NCD prevalence. Adapted from ISPOR Budget Impact-Principals of Good Practice Taskforce [17]. Chronic Disease Man-
agement (CDM); cardiovascular disease (CVD); diabetes mellitus (DM); Ministry of Health (MOH); Academic Model Providing Access to Health-
care (AMPATH); AMPATH Medical Records System (AMRS).
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(SD$10,404). This is unsurprising given that MTRH functions
as both a Cardiac Center of Excellence and a referral hospital,
seeing both the largest volume of and most complex patients
who require a higher proportion of clinical specialists. With
the exception of the referral hospital (MTRH), travel costs by
visit ranged from $0.80 to $2.99 across all levels of care. Staff
costs were evenly distributed by patient visits, with annual
costs of $805 per dispensary, $2,002 per health centre,
$3,662 per primary hospital and $18,314 at MTRH.
Table 2 presents the difference in patient visit costs for
CDM program integration within the HIV care platform com-
pared to the primary care platform. Controlling for patient vis-
its, health care level, transportation costs, and date (month
and year), NCD care provision within the HIV care platform
was $1 (95% confidence interval (CI), 2.11 to 0.11) less
expensive per patient visit compared to care provision added
to the primary care platform.
Under the constant percent growth patient enrolment sce-
nario, the incremental five-year budget impact of scaling up
CDM across all CDM counties was $3,088,970, while under
the steady state scale-up scenario the incremental five-year
budget impact was $3,451,732, with a total number of 26,765
new patients enrolled (Table 3). In Bungoma county, the bud-
get impact under the percent growth scale-up and steady-
state scenarios is $539,820, and $722,798 respectively, a
34% difference. In Kisumu county, the incremental five-year
budget impact under the percent growth scale-up is $287,977
and $390,183 under the steady state scale-up, representing a
35% difference. In Nandi county, the incremental five-year
budget impact under the percent growth scale-up and steady
state is $2,274,405 and 336,493 respectively, a 23% differ-
ence. In Trans Nzoia county, the incremental five-year budget
impact under the percent growth scale-up is $187,041 and
$202,572 under the steady state scale-up scenario. Savings
from the percent growth scale-up scenario in Trans Nzoia is
minimal at only 8%. The differences in costs under the two
scale-up scenarios are shown for the whole programme in
Figure 3, which presents the incremental cost of scale-up by
total number of covered patients under all scenarios including
sensitivity analysis.
Table 4 presents (1) the 2019 annual healthcare budget for
the six counties where AMPATH operates the CDM pro-
gramme, and (2) the projected total program budget for the
most expensive program year for the modelled time horizon
(year 2025). The projected per county CDM budget also
includes care costs for patients enrolled prior to the scale-up,
which allows for a more comprehensive assessment of the
proportion of the annual budget that would be needed to pro-
vide CDM care to 50% of the eligible population by 2025.
The proportion of annual county budget cost is less than 0.9%
in every county and scale-up scenario.
3.1 | Sensitivity analysis
Varying the distribution of new patient enrolment across facil-
ity types led to limited variation in budget impact (Tables S16,
S17,S18,S19,S20,S21). The most expensive distribution was
more heavily weighted towards the dispensaries and health
centres, while the least expensive option was the one based
on historical expansion distribution across facility type. The
budget impact using the maximum salaries was between 44%
and 48% higher than the budget impact at the lowest level of
salaries. The total budget impact of varying the transport costs
was minimal (Tables S22,S23).
4 | DISCUSSION
To the best of our knowledge, this is the first study to esti-
mate the health system delivery costs for a public NCD
Figure 2. Monthly Programmatic Costs by Facility, and Average Total Cost per Month from January 2014 to 2018. Moi Teaching and Referral
Hospital (MTRH)
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chronic care program in western Kenya integrated into both
HIV and primary care platforms, and the first to provide the
public health budget impact of scaling up integrated CDM in
the region, which results in several policy implications.
While salary for clinicians and programmatic staff were the
largest costs, task shifting between clinician levels to increase
care coverage while still offering comprehensive care for
complex cases reduces costs [9,27-29]. However, human
resource constraints may limit proposed scale-up, and needs
to be monitored using the CDM needs-based health work-
force assessment that can approximate the gaps in human
resources as the program grows [26].
The average per patient visit cost was $10.42, and adding
CDM to the HIV care platform cost $1.00 less than adding
the same CDM services to the primary care platform. How-
ever, these findings were not statistically significant so should
be considered with caution during program policy. The num-
ber of patient visits, facility level and travel demands are dif-
ferent for more remote HIV clinics compared to central
hospitals and health centres. Though economies of scale at
hospitals would result in a lower overall program budget for
these facilities, a key benefit of the CDM programme is its
ability to improve access to chronic care in underserved and
rural areas. Thus, decision-makers will need to balance effi-
cient care delivery with investments to improve access to
care for remote populations.
The budget projections were sensitive to the scale-up
model, with average five-year cost savings of 12% if using
scaling up with fixed percent growth instead of steady-state
enrolment. The model was also sensitive to a lesser extent to
the distribution of patient enrolment across facility types,
which allows for selection of a lower budget option despite
rising patient-visits. While the growth in number of patients
over five years is large, the evidence from Busia and Uasin
Gishu demonstrates that both rapid programme growth and
achievement of the target population coverage are possible.
The total annual CDM budget of the fixed percent growth
model in 2025, which is the most expensive year of the pro-
gramme, was very small compared to the total budget. While
healthcare financing can be variable, county health budgets
have increased by more than 1% every year since 2015. This
signifies that the count budgets can support CDM me
growth without detracting from existing services [30].
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Table 2. Per patient visit costs by care delivery platform
Coef. P> t [95% Conf. interval]
HIV care platform 1.00 0.079 (2.11, 0.12)
Monthly patient visits 0.012 0.002 (0.004, 0.019)
Log (monthly patient visits) 5.71 <0.001 (6.22, 5.19)
Facility level
Health centre 0.57 0.353 (1.77, 0.63)
Hospital 0.48 0.455 (0.77, 1.73)
Referral hospital 20.27 <0.001 (16.68, 23.87)
Date (month/year) 0.015 0.317 (0.044, 0.014)
Transportation costs 0.069 <0.001 (0.061, 0.077)
_cons 38.99 <0.001 (19.56, 58.41)
Osetinsky et al. Journal of the International AIDS Society 2020, 23(S1):e25496
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25496/full | https://doi.org/10.1002/jia2.25496
59
Our study has some limitations. We did not explicitly model
changes in testing, linkage to care, or changing prevalence of
HIV or NCDs. Using set growth rates we are instead able to
project easily interpretable estimates of the budget impact, and
our approach is consistent with the ISPOR guidelines which
prefer static models for shorter timelines [17]. We also did not
Table 3. Budget Impact of CDM Scale-Up from 2021 to 2025 in US ($)
Newly enrolled
patients
Steady state patient enrolment Percent growth target
Saving from using percent scale
up, %Mean (Min: Max) Mean (Min: Max)
Bungoma 12,834 722,798 (556,910: 861,194) 539,820 (439,830: 642,963) 34
Kisumu 7,578 390,183 (349,735: 510,658) 287,977 (251,687: 367,500) 3
Nandi 5,861 336,493 (271,193: 395,645) 274,405 (222,323: 324,735) 23
Trans
Nzoia
3,572 202,573 (165,079: 240,893) 187,041 (152,491: 222,585) 8
Total 26,765 3,451,732 (2,600,555:
4,341,799)
3,088,928 (2,323,970:
3,891,191)
12
a
Chronic Disease Management (CDM)
Figure 3. Budget Impact of Scaling up CDM to the treatment targets under two scale-up models: Incremental costs of the additional
patients from 2021 to 2025. Chronic Disease Management (CDM)
Table 4. County level annual budget and proportion of budget used by Chronic Disease Management (CDM) in 2025 US($)
Annual Healthcare
Budget (2019)
Steady State Patient Enrolment
2025 CDM Budget
Percent Growth Target
2025 CDM Budget
Proportion of Healthcare
Budget, %
Bungoma 30,862,211 263,006 268,323 0.4
Busia 16,908,129 104,881 104,881 0.6
Kisumu 31,039,241 141,750 150,994 0.2
Nandi 19,132,221 122,278 124,568 0.3
Trans Nzoia 21,672,952 110,654 110,715 0.3
Uasin Gishu 20,764,446 163,892 163,892 0.8
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account for health system investments to improve pharmacy
access or address medication stock outs [31]. In some cases
the CDM programme operates concurrently with a Revolving
Funds Pharmacy (RFP) model which uses revenue generated
from mediation sales to sustainably resupply medications, and
is used as a backup in the event of a stock-out at the MoH
facility or in the absence of an MoH pharmacy [32]. After the
initial startup costs for purchasing medications and hiring phar-
macists, the RFP model is largely self-sustaining [21].
AMPATH’s CDM programme has lower average per visit
costs compared to other public programs that offer chronic
NCD care in Kenya, and substantially lower costs than hospi-
talizations related to untreated NCDs [33,34]. This difference
should not disqualify the generalizability of our findings and
recommends the expansion of the CDM programme. A chal-
lenge in shaping health policy in Kenya is the lack of available
evidence indicating that translation of global NCD recommen-
dations is successful in the local context [35]. Certain costs
included in this study such as the cost of travel specific to
AMPATH clinics, and the differences in provider and staff pay
grades compared to the public sector may result in higher
total and per patient costs. Therefore, our budget projections
can be seen as the higher end of the BIA estimations. The per
capita budgets for the counties included in this study are con-
sistent with other counties, which indicates that the low bud-
get impact observed in our projections can be expected to be
similar for other countries. AMPATH’s CDM programme
largely serves rural and peri-urban clinics, and expansion of
this program is relevant for the 73% of the national popula-
tion that reside in Kenya’s rural areas. For counties where
AMPATH does not have a presence, additional costs for elec-
tronic medical records systems will need to be considered in
addition to the costs for technicians and data teams included
in our analyses [36].
5 | CONCLUSIONS
By relying on task-shifting and diverse facility partnerships, the
integrated CDM programme can increase access to chronic
NCD care with minimal budget impact in western Kenya. Our
budget impact model was highly sensitive to scale-up and
human resource costs, and was influenced to a lesser extent by
facility mix and travel costs. The programmatic costing and BIA
estimates provide policy makers with a framework to estimate
resource needs to expand NCD care within existing health sys-
tem structures, and the flexibility to integrate care within HIV
or primary care platforms based on county-level capacity.
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Box 1. Research agenda
This research aims to:
• Present findings from a novel budget impact analysis conducted for a dedicated chronic NCD care programme in East
Africa.
• Measure clinic-level monthly costs of the AMPATH Chronic Disease Management (CDM) programme in western Kenya,
which builds on an establish HIV service platform to provide chronic NCD care to more than 15,000 patients.
• Model the budget impact of increasing the number of annual CDM patients to reach 50% of the eligible population in six
counties by 2025.
• Vary the provider costs and type of offering facilities to assess the optimal scenarios under which the CDM program can
be scale-up with minimal budget impact.
Box 2. Policy implications and future directions
• Scaling up CDM to the target population coverage under a constant annual growth scenario has a lower five-year budget
impact than a steady-stage enrolment.
• The budget impact of scaling up CDM under to the target patient coverage is $3,088,928 ($2,323,970 to $3,891,191).
• The static model used in this BIA is consistent with ISPOR guidelines, which contributes a reliable and adaptable framework
for policy makers to estimate the resources required to layer NCD care onto existing health system structures.
• Task-shifting chronic NCD care is a highly cost-saving approach for reaching a wider, rural patient population and one that
should be emphasized during scale-up activities.
• The annual total cost of CDM at the target coverage is less than 1% of each county’s annual health budget.
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